Search results
Showing 2451 to 2500 of 4091 results for patient
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation
In development Reference number: GID-IPG10416 Expected publication date: 25 February 2026
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
Inform the clinical governance leads in their NHS trusts. Ensure that patients understand the procedure's safety and efficacy, as well...
NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions
Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.
Inform the clinical governance leads in their NHS trusts. Ensure that patients and their carers understand the procedure's safety and...
t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)
NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes .
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
NICE has developed a medtech innovation briefing (MIB) on Neon EEG electrode for EEG monitoring in newborns .
Summary of the evidence on desflurane for maintenance of anaesthesia
Day-to-day decision making is the responsibility of NICE's executive team.
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.
improved or managed during the hospital stay are most prevalent in older patients who fall in inpatient settings in the UK? Any...
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .
pharmacological pain management (in both pre-hospital and hospital settings) in patients with major trauma? Any explanatory notes(if...
observed health-related quality of life values (such as EQ 5D scores) in patients with myelodysplastic syndromes, chronic myelomonocytic...
This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.
View quality statements for QS79Show all sections
Sections for QS79
- Quality statements
- Quality statement 1: Diagnosis of idiopathic pulmonary fibrosis
- Quality statement 2: Access to a specialist nurse
- Quality statement 3: Assessment for oxygen therapy
- Quality statement 4: Pulmonary rehabilitation
- Quality statement 5: Palliative care
- Update information
- About this quality standard
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)
Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making
Evidence-based recommendations on rucaparib (Rubraca) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse? Any...
Leadless cardiac pacemaker implantation for bradyarrhythmias
In development Reference number: GID-IPG10340 Expected publication date: 25 February 2026
NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .
This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.
of patient selection (including number of patients dependent on dialysis) details of the procedure technique duration of...
ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)
NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .
prescribing Measuring the use of NICE guidance Into practice resources Patient decision aids Implementation help and advice Cost saving,...
This quality standard covers the investigation and recognition of suspected cancer, and referral to specialist cancer services for adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS124Show all sections
Sections for QS124
- List of quality statements
- Quality statement 1: Direct access to diagnostic tests
- Quality statement 2: Urgent direct access endoscopy for oesophageal or stomach cancer
- Quality statement 3: Testing for blood in faeces
- Quality statement 4: Encouraging attendance at cancer services
- Update information
- About this quality standard
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)
Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)
Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
identified influence patient management. The presence of metastasis or a synchronous second primary cancer at presentation is rare in...
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
initial diagnosis onwards. There are indications from research literature and patient reports that these needs are currently unmet....
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)
NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .
Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.
during the evaluation of these treatments. This was informed by input from patient organisation groups, our partners and international...
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.
Give patients clear information to support shared decision making , including NICE's information for the public . Ensure that...
Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.
Current research is often limited by attempting to explain individual patient level outcomes as a function of aggregate or summary...
Suggested PICO (Population, Intervention, Comparator, Outcome) P: patients with a confirmed diagnosis of COVID-19 in hospital or...